LU91703I2 - Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®) - Google Patents

Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®)

Info

Publication number: LU91703I2
Authority: LU; Luxembourg
Prior art keywords: galactosidase; mammalian cell; acid residues; biologically active; sialic acid
Prior art date: 1992-11-30

Application number

LU91703C

Other languages

English (en)

Original Assignee

Sinai School Medicine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-30

Filing date

2010-06-24

Publication date

2010-08-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25529958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91703(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-06-24 Application filed by Sinai School Medicine filed Critical Sinai School Medicine

2010-08-24 Publication of LU91703I2 publication Critical patent/LU91703I2/fr

Links

108010056760 agalsidase beta Proteins 0.000 title 2
229960004470 agalsidase beta Drugs 0.000 title 1
KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 title 1
229940014516 fabrazyme Drugs 0.000 title 1
210000004962 mammalian cell Anatomy 0.000 abstract 4
210000004027 cell Anatomy 0.000 abstract 2
238000004113 cell culture Methods 0.000 abstract 2
238000012258 culturing Methods 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000009450 sialylation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Virology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Enzymes And Modification Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU91703C 1992-11-30 2010-06-24 Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®) LU91703I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/983,451 US5401650A (en)	1990-10-24	1992-11-30	Cloning and expression of biologically active α-galactosidase A
EP94902448A EP0670896B2 (fr)	1992-11-30	1993-11-30	Clonage et expression d'alpha-galactosidase a biologiquement active
EP00200454A EP1020528A3 (fr)	1992-11-30	1993-11-30	Méthode de production de protéines secrétées

Publications (1)

Publication Number	Publication Date
LU91703I2 true LU91703I2 (fr)	2010-08-24

Family

ID=25529958

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU91703C LU91703I2 (fr)	1992-11-30	2010-06-24	Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®)
LU91704C LU91704I2 (fr)	1992-11-30	2010-06-24	Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LU91704C LU91704I2 (fr)	1992-11-30	2010-06-24	Agalsidase alfa et ses dérivées pharmaceutiquementacceptables (REPLAGAL®)

Country Status (14)

Country	Link
US (2)	US5401650A (fr)
EP (4)	EP1020528A3 (fr)
JP (2)	JP4005629B2 (fr)
AT (2)	ATE464386T1 (fr)
AU (1)	AU691795B2 (fr)
CA (1)	CA2150555C (fr)
DE (3)	DE69334327D1 (fr)
DK (3)	DK2210947T3 (fr)
ES (3)	ES2431293T3 (fr)
IL (4)	IL220132A0 (fr)
LU (2)	LU91703I2 (fr)
PT (3)	PT1942189E (fr)
SE (1)	SE2210947T5 (fr)
WO (1)	WO1994012628A1 (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6846968B1 (en) *	1988-02-26	2005-01-25	Large Scale Biology Corporation	Production of lysosomal enzymes in plants by transient expression
US20040064855A1 (en) *	1988-02-26	2004-04-01	Large Scale Biology Corporation	Production of lysosomal enzymes in plants by transient expression
US5179023A (en) *	1989-03-24	1993-01-12	Research Corporation Technologies, Inc.	Recombinant α-galactosidase a therapy for Fabry disease
AU688310B2 (en) *	1993-03-26	1998-03-12	New York Blood Center, Inc., The	Recombinant alpha-N-acetylgalactosaminidase enzyme and cDNA encoding said enzyme
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
HU227189B1 (en) *	1996-09-13	2010-10-28	Transkaryotic Therapies	Therapy for alpha-galactosidase a deficiency
AU2012227349B2 (en) *	1996-09-13	2015-12-24	Shire Human Genetic Therapies, Inc.	Therapy for alpha-galactosidase A deficiency
US6083725A (en)	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) *	2003-04-27	2003-11-23	Metabogal Ltd	Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US6455037B1 (en) *	1996-11-01	2002-09-24	Mount Sinai School Of Medicine Of The City University Of New York	Cells expressing an αgala nucleic acid and methods of xenotransplantation
US6210666B1 (en)	1997-10-21	2001-04-03	Orphan Medical, Inc.	Truncated α-galactosidase A to treat fabry disease
EP1658857A1 (fr) *	1997-10-29	2006-05-24	Genzyme Corporation	Compositions et méthodes pour le traitement de maladies lysosomales
WO2000009153A1 (fr) *	1997-10-29	2000-02-24	Genzyme Corporation	Compositions et procedes pour traiter les maladies lysosomiales
CA2354846A1 (fr) *	1998-12-23	2000-06-29	Regeneron Pharmaceuticals, Inc.	Technique permettant d'accroitre l'activite biologique de ligands
AU2016250357B2 (en) *	1999-03-11	2018-11-01	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) *	1999-03-11	2016-07-28	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
US6534300B1 (en)	1999-09-14	2003-03-18	Genzyme Glycobiology Research Institute, Inc.	Methods for producing highly phosphorylated lysosomal hydrolases
US6770468B1 (en)	1999-09-14	2004-08-03	Genzyme Glycobiology Research Institute, Inc.	Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
CN1312383A (zh) *	2000-03-07	2001-09-12	上海博德基因开发有限公司	一种新的多肽——人alpha－半乳糖苷酶A－11和编码这种多肽的多核苷酸
US7138262B1 (en)	2000-08-18	2006-11-21	Shire Human Genetic Therapies, Inc.	High mannose proteins and methods of making high mannose proteins
US7629309B2 (en) *	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
AU2002256423B2 (en) *	2001-04-30	2008-07-24	Zystor Therapeutics, Inc.	Subcellular targeting of therapeutic proteins
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US20040005309A1 (en) *	2002-05-29	2004-01-08	Symbiontics, Inc.	Targeted therapeutic proteins
JP4742191B2 (ja) *	2001-06-14	2011-08-10	独立行政法人産業技術総合研究所	糖蛋白質およびその製造方法
US7767415B2 (en)	2001-09-25	2010-08-03	Velico Medical, Inc.	Compositions and methods for modifying blood cell carbohydrates
EP2305312B1 (fr)	2001-10-10	2015-03-04	ratiopharm GmbH	Remodelage et glycoconjugation de l'hormone folliculo-stimulante (FSH)
US20030072761A1 (en) *	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
US20030124652A1 (en) *	2001-12-21	2003-07-03	Novazyme Pharmaceuticals, Inc.	Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6800472B2 (en) *	2001-12-21	2004-10-05	Genzyme Glycobiology Research Institute, Inc.	Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) *	2001-12-21	2005-06-14	Genzyme Glycobiology Research Institute, Inc.	Soluble GlcNAc phosphotransferase
AU2003224880A1 (en) *	2002-04-05	2003-10-27	Genzyme Corporation	Methods of enhancing lysosomal storage disease therapy
ES2367257T3 (es)	2002-04-25	2011-10-31	Shire Human Genetic Therapies, Inc.	Tratamiento de deficit de alfa-galactosidasa a.
CN102586205A (zh)	2003-01-31	2012-07-18	纽约大学西奈山医学院	酶和酶的活性部位特异性陪伴分子的组合
EP1615945B1 (fr)	2003-04-09	2011-09-28	BioGeneriX AG	Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
US7951557B2 (en)	2003-04-27	2011-05-31	Protalix Ltd.	Human lysosomal proteins from plant cell culture
BRPI0416216A (pt) *	2003-11-12	2006-12-26	Amicus Therapeutics Inc	composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
JP4914224B2 (ja) *	2004-02-10	2012-04-11	バイオマリンファーマシューティカルインコーポレイテッド	酸性αグルコシダーゼおよびそのフラグメント
US8889127B2 (en) *	2004-07-01	2014-11-18	Icahn School Of Medicine At Mount Sinai	Targeted protein replacement for the treatment of lysosomal storage disorders
CN101389273B (zh) *	2004-08-05	2012-09-05	贝勒研究院	基因或药物递送系统
EP3782655A1 (fr)	2005-05-17	2021-02-24	Amicus Therapeutics, Inc.	Procédé pour le traitement de la maladie de pompe au moyen de 1-désoxynojirimycine et de ses dérivés
US8470318B2 (en)	2005-11-07	2013-06-25	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
BRPI0618583A2 (pt) *	2005-11-18	2011-09-06	Tokyo Metropolitan Org Med Res	enzima altamente funcional tendo especifidade ao substrato modificada
AU2007212021B2 (en)	2006-02-07	2013-06-06	Takeda Pharmaceutical Company Limited	Stabilized compositions of proteins having a free thiol moiety
GB0606190D0 (en)	2006-03-28	2006-05-10	Isis Innovation	Construct
NZ572379A (en) *	2006-04-05	2012-06-29	Univ Rockefeller	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2099523A2 (fr) *	2006-11-13	2009-09-16	ZyStor Therapeutics , Inc.	Méthodes de traitement de la maladie de pompe
ES2660667T3 (es)	2007-05-07	2018-03-23	Protalix Ltd.	Biorreactor desechable a gran escala
BRPI0815324A2 (pt) *	2007-08-20	2015-07-14	Protalix Ltd	"conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
SI2252313T1 (sl) *	2008-02-12	2015-08-31	Amicus Therapeutics, Inc.	Postopek napovedovanja odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
EA201001678A1 (ru)	2008-04-22	2011-06-30	Те Рокфеллер Юниверсити	Способы идентификации противовоспалительных соединений
US20110223147A1 (en)	2008-05-07	2011-09-15	Zystor Therapeutics, Inc.	Lysosomal targeting peptides and uses thereof
US8592555B2 (en) *	2008-08-11	2013-11-26	Emd Millipore Corporation	Immunoglobulin-binding proteins with improved specificity
KR20110076906A (ko) *	2008-09-30	2011-07-06	아보트 러보러터리즈	개선된 ｒｎａ 디스플레이 방법
SG195555A1 (en) *	2008-12-24	2013-12-30	Emd Millipore Corp	Caustic stable chromatography ligands
US9050276B2 (en)	2009-06-16	2015-06-09	The Trustees Of Columbia University In The City Of New York	Autism-associated biomarkers and uses thereof
ES2758827T3 (es)	2009-06-17	2020-05-06	Biomarin Pharm Inc	Formulaciones para enzimas lisosómicas
NZ713967A (en)	2009-07-28	2017-01-27	Shire Human Genetic Therapies	Compositions and methods for treating gaucher disease
US9194011B2 (en)	2009-11-17	2015-11-24	Protalix Ltd.	Stabilized alpha-galactosidase and uses thereof
JPWO2011108451A1 (ja) *	2010-03-01	2013-06-27	日本ケミカルリサーチ株式会社	遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
US20130017169A1 (en)	2010-03-02	2013-01-17	Protalix Ltd.	Multimeric forms of therapeutic proteins and uses thereof
AU2011222452B2 (en) *	2010-03-02	2015-09-03	Protalix Ltd.	Stabilized alpha-galactosidase and uses thereof
EP2595651B1 (fr)	2010-07-19	2017-03-29	Shire Human Genetic Therapies, Inc.	Lignée cellulaire optimisée pour le codon de récepteur de mannose de type c 1 (mrc1) et ses utilisations
US8679478B2 (en)	2010-10-04	2014-03-25	Duke University	Methods of lysosomal storage disease therapy
BR112013009196A2 (pt)	2010-10-15	2020-08-25	The Trustees Of Columbia University In The City Of New York	usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
PL2635299T3 (pl)	2010-11-02	2020-03-31	The Trustees Of Columbia University In The City Of New York	Sposoby leczenia zaburzeń utraty włosów
BR112013018516B1 (pt)	2011-01-20	2023-11-07	Protalix Ltd	Construto de expressão de ácido nucleico, método de produção de uma proteína alfa-galactosidase humana recombinante, proteína alfagalactosidase humana, composição farmacêutica, e, uso de uma proteína alfagalactosidase humana ou de uma composição
SG186552A1 (en)	2011-06-08	2013-01-30	Emd Millipore Corp	Chromatography matrices including novel staphylococcus aureus protein a based ligands
DK2753346T3 (da)	2011-09-07	2020-05-25	Sinai School Medicine	Ceramidase og celledifferentiering
US9623090B2 (en)	2012-03-02	2017-04-18	Shire Human Genetic Therapies, Inc.	Compositions and methods for treating type III gaucher disease
US9404100B2 (en)	2012-03-07	2016-08-02	Amicus Therapeutics, Inc.	High concentration alpha-glucosidase compositions for the treatment of Pompe disease
WO2013139861A1 (fr)	2012-03-20	2013-09-26	Luc Montagnier	Procédés et compositions pharmaceutiques pour le traitement de troubles du syndrome de l'autisme
PL2830662T3 (pl)	2012-03-29	2019-02-28	The Trustees Of Columbia University In The City Of New York	Sposoby leczenia zaburzeń utraty włosów
EP2854910B1 (fr)	2012-06-01	2020-04-15	Icahn School of Medicine at Mount Sinai	Niveaux de céramide dans le traitement et la prévention d'infections
WO2014016873A1 (fr)	2012-07-26	2014-01-30	Jcr Pharmaceuticals Co., Ltd.	Procédé de production d'alpha-galactosidase a humaine recombinante
JP6226435B2 (ja) *	2012-07-26	2017-11-08	Ｊｃｒファーマ株式会社	組換えヒトα−ガラクトシダーゼＡの製造方法
EP3659619A1 (fr)	2013-03-14	2020-06-03	Icahn School of Medicine at Mount Sinai	Compositions céramidase d'acide thérapeutiques et leurs procédés de fabrication et d'utilisation
US9889203B2 (en) *	2013-03-15	2018-02-13	Amicus Therapeutics, Inc.	Chemical crosslinkers
KR102749545B1 (ko) *	2013-09-16	2025-01-07	젠자임 코포레이션	세포 배양물을 가공하는 방법 및 시스템
TWI793159B (zh)	2013-10-23	2023-02-21	美商健臻公司	重組醣蛋白及其用途
US9682123B2 (en)	2013-12-20	2017-06-20	The Trustees Of Columbia University In The City Of New York	Methods of treating metabolic disease
FI3201320T3 (fi)	2014-09-30	2024-01-08	Amicus Therapeutics Inc	Erittäin tehokas hapan alfa-glukosidaasi parannetuilla hiilihydraateilla
WO2016116966A1 (fr) *	2015-01-22	2016-07-28	Jcr Pharmaceuticals Co., Ltd.	Procédé de purification d'une alpha-galactosidase a recombinante humaine à partir de matériel contenant des protéines contaminantes des cellules hôtes
US9981021B1 (en)	2015-04-09	2018-05-29	Kinetiq, Inc.	Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
CA2997947A1 (fr)	2015-09-09	2017-03-16	The Trustees Of Columbia University In The City Of New York	Reduction du fragment c99 de l'app localise sur la membrane er-mam et procedes de traitement de la maladie d'alzheimer
US10940125B2 (en)	2015-09-18	2021-03-09	Duke University	Methods and compositions for the treatment of steatosis-associated disorders
CA3010205A1 (fr)	2015-12-30	2017-07-06	Amicus Therapeutics, Inc.	Alpha-glucosidase acide amelioree pour le traitement de la maladie de pompe
KR20250050123A (ko)	2016-03-30	2025-04-14	아미쿠스 세라퓨틱스, 인코포레이티드	고 m6p 재조합 단백질의 선택 방법
AU2017239641A1 (en)	2016-03-30	2018-10-18	Amicus Therapeutics, Inc.	Formulations comprising recombinant acid alpha-glucosidase
NL2017294B1 (en)	2016-08-05	2018-02-14	Univ Erasmus Med Ct Rotterdam	Natural cryptic exon removal by pairs of antisense oligonucleotides.
US11154591B2 (en)	2016-10-14	2021-10-26	The Trustees Of Columbia University In The City Of New York	Methods of treating alcohol abuse disorder
PT3624831T (pt)	2017-05-15	2023-07-04	Amicus Therapeutics Inc	Alfa-glucosidase ácida humana recombinante
RU2698460C1 (ru) *	2019-03-28	2019-08-27	Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум"	Способ получения рекомбинантной в-1,4-галактозидазы bgaa из streptococcus pneumoniae
WO2021005176A1 (fr)	2019-07-09	2021-01-14	Genethon	Traitement de la glycogénose (gsd)
WO2022100748A1 (fr) *	2020-11-16	2022-05-19	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Virus adéno-associés recombinés à tropisme hépatique amélioré et leurs utilisations
CN112795583A (zh) *	2020-11-16	2021-05-14	上海大学	重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法
TW202309271A (zh) *	2021-04-20	2023-03-01	美商步行魚治療公司	細胞群、工程化ｂ細胞及其產生方法與用途、基因體編輯系統以及核酸構築體

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH585793A5 (fr) *	1974-02-01	1977-03-15	Nestle Sa
JPS5322158B2 (fr) *	1974-05-02	1978-07-06
IT1130242B (it) *	1980-02-01	1986-06-11	Anic Spa	Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US4925796A (en) *	1986-03-07	1990-05-15	Massachusetts Institute Of Technology	Method for enhancing glycoprotein stability
US5047335A (en) *	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
EP0463109A4 (en) *	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
US5032519A (en) *	1989-10-24	1991-07-16	The Regents Of The Univ. Of California	Method for producing secretable glycosyltransferases and other Golgi processing enzymes
DE4028800A1 (de) *	1990-09-11	1992-03-12	Behringwerke Ag	Gentechnische sialylierung von glykoproteinen
US5382524A (en) *	1990-10-24	1995-01-17	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-n-acetylgalactosaminidase

1992
- 1992-11-30 US US07/983,451 patent/US5401650A/en not_active Expired - Lifetime
1993
- 1993-11-30 IL IL220132A patent/IL220132A0/en unknown
- 1993-11-30 WO PCT/US1993/011539 patent/WO1994012628A1/fr not_active Ceased
- 1993-11-30 AT AT07022356T patent/ATE464386T1/de active
- 1993-11-30 AT AT94902448T patent/ATE213020T1/de not_active IP Right Cessation
- 1993-11-30 DE DE69334327T patent/DE69334327D1/de not_active Expired - Lifetime
- 1993-11-30 DK DK10157183.4T patent/DK2210947T3/da active
- 1993-11-30 DE DE69331550T patent/DE69331550T3/de not_active Expired - Lifetime
- 1993-11-30 EP EP00200454A patent/EP1020528A3/fr not_active Ceased
- 1993-11-30 IL IL220131A patent/IL220131A0/en unknown
- 1993-11-30 ES ES10157183T patent/ES2431293T3/es not_active Expired - Lifetime
- 1993-11-30 IL IL200005A patent/IL200005A/en not_active IP Right Cessation
- 1993-11-30 PT PT07022356T patent/PT1942189E/pt unknown
- 1993-11-30 IL IL107814A patent/IL107814A/en active Protection Beyond IP Right Term
- 1993-11-30 PT PT101571834T patent/PT2210947E/pt unknown
- 1993-11-30 ES ES07022356T patent/ES2344431T3/es not_active Expired - Lifetime
- 1993-11-30 PT PT94902448T patent/PT670896E/pt unknown
- 1993-11-30 EP EP07022356A patent/EP1942189B1/fr not_active Expired - Lifetime
- 1993-11-30 EP EP10157183.4A patent/EP2210947B1/fr not_active Expired - Lifetime
- 1993-11-30 AU AU56817/94A patent/AU691795B2/en not_active Expired
- 1993-11-30 DK DK07022356.5T patent/DK1942189T3/da active
- 1993-11-30 DE DE122010000028C patent/DE122010000028I1/de active Pending
- 1993-11-30 DK DK94902448T patent/DK0670896T3/da active
- 1993-11-30 SE SE10157183T patent/SE2210947T5/xx unknown
- 1993-11-30 ES ES94902448T patent/ES2168101T5/es not_active Expired - Lifetime
- 1993-11-30 CA CA2150555A patent/CA2150555C/fr not_active Expired - Lifetime
- 1993-11-30 JP JP51342394A patent/JP4005629B2/ja not_active Expired - Lifetime
- 1993-11-30 EP EP94902448A patent/EP0670896B2/fr not_active Expired - Lifetime
1994
- 1994-06-17 US US08/261,577 patent/US5580757A/en not_active Expired - Lifetime
2003
- 2003-12-01 JP JP2003401467A patent/JP3598302B2/ja not_active Expired - Lifetime
2010
- 2010-06-24 LU LU91703C patent/LU91703I2/fr unknown
- 2010-06-24 LU LU91704C patent/LU91704I2/fr unknown

Also Published As

Publication number	Publication date
DE69334327D1 (de)	2010-05-27
CA2150555C (fr)	2010-11-02
IL220131A0 (en)	2012-07-31
IL107814A (en)	2012-12-31
EP0670896B2 (fr)	2005-04-27
PT670896E (pt)	2002-07-31
PT2210947E (pt)	2013-10-23
AU5681794A (en)	1994-06-22
WO1994012628A1 (fr)	1994-06-09
JP3598302B2 (ja)	2004-12-08
ATE464386T1 (de)	2010-04-15
US5401650A (en)	1995-03-28
US5580757A (en)	1996-12-03
DK2210947T3 (da)	2013-10-07
JPH08503615A (ja)	1996-04-23
JP2004121260A (ja)	2004-04-22
ES2168101T3 (es)	2002-06-01
EP1020528A2 (fr)	2000-07-19
DE69331550D1 (de)	2002-03-21
DK1942189T3 (da)	2010-06-07
EP2210947A2 (fr)	2010-07-28
JP4005629B2 (ja)	2007-11-07
IL220132A0 (en)	2012-07-31
PT1942189E (pt)	2010-05-28
DE69331550T3 (de)	2006-06-29
ATE213020T1 (de)	2002-02-15
AU691795B2 (en)	1998-05-28
EP1942189A3 (fr)	2008-09-10
DK0670896T3 (da)	2002-05-27
DE122010000028I1 (de)	2010-08-12
EP1942189A2 (fr)	2008-07-09
EP0670896A4 (fr)	1997-08-20
EP0670896A1 (fr)	1995-09-13
EP1942189B1 (fr)	2010-04-14
EP1020528A3 (fr)	2000-10-04
ES2431293T3 (es)	2013-11-25
EP0670896B1 (fr)	2002-02-06
ES2168101T5 (es)	2005-10-16
ES2344431T3 (es)	2010-08-26
SE2210947T5 (fr)	2015-02-03
CA2150555A1 (fr)	1994-06-09
EP2210947A3 (fr)	2010-10-06
IL107814A0 (en)	1994-02-27
DE69331550T2 (de)	2002-09-26
IL200005A (en)	2013-09-30
EP2210947B1 (fr)	2013-07-17
LU91704I2 (fr)	2010-08-24

Publication	Publication Date	Title
LU91703I2 (fr)	2010-08-24	Agalsidase beta et ses dérivées pharmaceutiquementacceptables (FABRAZYME®)
ATE331731T1 (de)	2006-07-15	Verfahren zur herstellung von diphtheria toxin
FR2726003B1 (fr)	2002-10-18	Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
ES8202362A1 (es)	1982-01-01	Procedimiento para preparar un acido desoxi-ribonucleico (adn) recombinante
EP0111389A3 (fr)	1985-08-14	Hormone de croissance porcine substantiellement pure, séquences d'ADN pour celle-ci et vecteurs d'expression et microorganismes transfectés pour la production de l'hormone de croissance porcine
ES2188708T3 (es)	2003-07-01	Metodo de produccion de acido l-lactico con alta pureza optica utilizando cepas de bacillus.
EP1497415A4 (fr)	2006-03-22	Recepteur de cytokine
KR910006483A (ko)	1991-04-29	재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도
EP0837931A4 (fr)	1999-06-02	Procede d'expression et d'isolation de molecules biologiquement actives dans l'urine
BR8103872A (pt)	1982-03-09	Processo de preparacao de cultura biologicamente pura de uma variante do microorganismo clostridum thermoaceticum cultura resultante ,e processo para a conversao de carboidraatos de acido acetico
EP1060241B2 (fr)	2010-10-20	Preparation de cellules pour la production de substances biologiques
DE59611099D1 (de)	2004-11-04	Verfahren zur Nutzung des Hefe-ADH-II-Promotorsystems zur biotechnologischen Produktion heterologer Proteine in hohen Ausbeuten
ATE145670T1 (de)	1996-12-15	Verfahren zur fermentativen herstellung von 2- hydroxyphenylessigsäure
DE3868712D1 (de)	1992-04-09	Ein neues antibiotikum, fumifungin, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel.
ZA878543B (en)	1988-10-26	Method for the preparation of optically active bicyclo(3.3.0.)-octanedionecarboxylic acid esters
CA2133345A1 (fr)	1993-10-14	Methode pour limiter la survie de microorganismes obtenus par voie genetique dans leur milieu
TH7253B (th)	2002-01-11	กระบวนการสำหรับผลิตอาเวอร์เมคตินbและเชื้อสำหรับผลิตสารเหล่านี้
JPS5668395A (en)	1981-06-09	Production of d(-)-beta-hydroxyisobutyric acid
TH9081A (th)	1991-07-01	กระบวนการสำหรับผลิตอาเวอร์เมคตินbและเชื้อสำหรับผลิตสารเหล่านี้
JPS6467193A (en)	1989-03-13	Production of 4-hydroxy-2,2,6-trimethylcyclohexanone
HK1030628C (en)	2007-04-27	Preparation of cells for production of biologicals
UA10461A (uk)	1996-12-25	Іhдуктор іhтерфероhу в клітиhах ссавців, які культивуються